Previous Article | Next Article ![]()
Applied and Environmental Microbiology, April 2002, p. 1509-1515, Vol. 68, No. 4
0099-2240/02/$04.00+0 DOI: 10.1128/AEM.68.4.1509-1515.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Endotoxin Binding in Determining Potency during Lepidopteran Larval Development
Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, United Kingdom
Received 15 October 2001/ Accepted 10 January 2002
|
|
|---|
|
|
|---|
endotoxins are a family of insecticidal proteins produced by Bacillus thuringiensis during sporulation. These toxins are typically found in parasporal crystals that are released into the environment with the bacterial spores. Numerous
endotoxins produced by B. thuringiensis have been identified and are grouped on the basis of sequence homology and insect specificity (40). The Cry1 toxins are a group of
endotoxins that principally target lepidopteran species, including several important crop pests.
The mechanism of action of the Cry1
endotoxins begins with solubilization of the protoxin in the alkaline larval midgut, followed by proteolytic processing by midgut proteases (40). The stable 60- to 65-kDa toxins then bind to midgut receptors and insert into the apical membrane of brush border epithelial cells to form pores. These pores disrupt functional membrane processes and are ultimately responsible for larval death (40).
Each type of Cry1 toxin has a unique spectrum of activity and targets only a small range of lepidopteran species. Within the small target ranges there are dramatic differences in potency between species that are often closely related (12, 15, 31). Indeed, the potency of a Cry1 toxin can significantly decrease as the larvae age (1, 38). Variations in the potencies of Cry1 toxins for different lepidopteran species and different larval stages may reflect differences in any one of the pre-binding, binding, and pore-forming events required for full toxicity. By discovering why Cry1 toxins exhibit such diverse potencies during larval development or for different species, it may be possible to engineer more potent toxins.
Early binding studies with purified radiolabeled Cry1
endotoxins and midgut brush border membrane vesicles (BBMV) showed that toxin-specific binding proteins are present and essential for toxicity (14, 48). The majority of Cry1 toxin binding proteins have been identified as aminopeptidases. Aminopeptidase N (APN) has been identified as a binding protein for the Cry1Ac toxin in Manduca sexta, Heliothis virescens, Lymantria dispar, and Plutella xylostella (9, 20, 33, 45). APN has also been identified as a Cry1Aa binding protein in Bombyx mori (18) and as a Cry1C binding protein in M. sexta (32). Other toxin binding proteins have been identified as cadherin-like glycoproteins that bind Cry1Aa and Cry1Ab in B. mori and M. sexta, respectively (36, 43, 44).
In this study, we were principally interested in assessing if Cry1 toxin binding is a key factor in determining differences in potency during larval aging. Five economically important crop pests, M. sexta, Pieris brassicae, Mamestra brassicae, Spodoptera exigua, and Agrotis ipsilon, were tested to determine their susceptibilities and characteristics of binding to Cry1Ac, Cry1Ca, Cry1J, and Cry1Ba at the neonate and third-instar stages of larval development. Our data show that for some, but not all, species-instar-toxin combinations, Cry1 toxin binding can indeed be a very strong indicator of potency.
|
|
|---|
Plasmids pMSV1Ac, pMSV1Ba, pMSV1Ca, and pMSV1J were introduced by electroporation into the acrystalliferous host B. thuringiensis subsp. israelensis 78/11 (49), and crystals containing toxin were recovered using sucrose density gradients by the method of Thomas and Ellar (42). Toxin yield was quantified by the method of Lowry et al. (29) using bovine serum albumin (BSA) as the standard.
Insects.
Insects were supplied as eggs by various laboratories as described below. Larvae were reared at 21 to 25°C by using cycles consisting of 16 h of light and 8 h of darkness and artificial diets. M. sexta (3), S. exigua (46), M. brassicae (8), and A. ipsilon (8) were raised on previously described diets. P. brassicae was raised on the M. brassicae diet supplemented with 16.2 g of dried organic cabbage powder per liter. M. sexta eggs were purchased from S. Reynolds (School of Biological Sciences, University of Bath, Bath, United Kingdom). M. brassicae and S. exigua eggs were purchased from T. Carty (N.E.R.C. Institute of Virology & Environmental Microbiology, Oxford, United Kingdom). S. exigua eggs were also kindly donated by DuPont. P. brassicae eggs were a gift from P. Jarrett (Horticultural Research International). A. ipsilon eggs were purchased from French Agricultural Research Inc., Lamberton, Minn.
Bioassays.
Bioassays were performed with neonate and third-instar larvae. For the bioassays, protoxin crystals were added to molten (55°C) diet and vortexed to mix the preparations thoroughly. The diet was then added to 1.5-ml Eppendorf tubes in 100-µl aliquots (neonate M. brassicae larvae and neonate S. exigua larvae), to 1.5-ml Eppendorf tubes in 500-µl aliquots (third-instar S. exigua larvae), to petri dishes in 5- to 10-ml aliquots (neonate A. ipsilon larvae and neonate and third-instar P. brassicae larvae), to 48-well culture plates in 300-µl aliquots (neonate M. sexta larvae), to individual wells of insect trays in 4- to 5-ml aliquots (third-instar M. sexta larvae and A. ipsilon larvae), and in 1-ml aliquots to 7-ml Greiner tubes (third-instar M. brassicae larvae). To prevent cannibalism, one larva of M. sexta, M. brassicae, or S. exigua or one third-instar larva of A. ipsilon was added to each aliquot of medium. P. brassicae and neonate A. ipsilon larvae were typically assayed in groups consisting of 20 individuals. Larval mortality and weight loss were assessed after 6 days, and 50% lethal concentrations (LC50) were determined by using the program of Lieberman (26) for probit analysis (11) and the results of at least three separate experiments in which there was less than 10% mortality of the controls.
Isolation of BBMV.
To determine whether differences in toxicity during larval development could be attributed to changes in binding characteristics, BBMV were prepared from neonate, third-instar, and fifth-instar larvae by differential centrifugation using the method of Carroll and Ellar (6). Escriche et al. (10) produced BBMV from whole and dissected midguts of Phthorimaea operculella and P. xylostella and found no significant differences in 125I binding characteristics, irrespective of the insect starting material, for either species. With this in mind, whole larvae were used to prepare BBMV from neonate larvae, since they were too small for dissection. So that data would be directly comparable, BBMV from third-instar larvae were also prepared from whole larvae. Dissected midguts were used to prepare BBMV from fifth-instar larvae. Whole larvae and dissected guts were collected over a period of several weeks, frozen in buffer A (250 mM sucrose, 5 mM Tris-HCl; pH 8) in liquid nitrogen, and stored at -70°C. The small biomass of the neonates limited the size of the BBMV preparation. Consequently, the preparations for all larval stages were scaled down to ensure that comparisons were relevant. The starting material was 0.5 g of material for all species except M. sexta, for which 2 g was used. The small working volumes were handled in 2-ml Eppendorf tubes and were centrifuged by using a fixed-angle rotor (Jouan MR22I). The final BBMV pellets were resuspended in 100 µl of buffer A and stored in aliquots at -20°C. Protein concentrations of the BBMV preparations were determined by the method of Bradford (4) with a Bio-Rad protein assay solution. Before BBMV were used in binding experiments, they were rapidly thawed at 37°C and placed on ice.
APN assays.
BBMV preparations were diluted (10 to 100 µg/ml) with buffer containing 250 mM sucrose and 5 mM Tris-HCl (pH 8) and were assayed for APN activity at 25°C by monitoring the change in absorbance at 405 nm using the chromogenic substrate L-leucine-p-nitroanilide (Sigma) (13). Standard concentrations of p-nitroanilide (Sigma) were used to calculate specific enzyme activities, and the absorption coefficient of p-nitroanilide was taken to be 9.9 liters·mmol-1·cm-1. Assays were done in the presence and in the absence of 0.1% (vol/vol) Triton X-100 to reveal any latent activity.
Toxin activation and purification.
Unlabeled protoxins used for competition assays were solubilized at room temperature in 50 mM Na2CO3 (pH 10)-10 mM dithiothreitol (DTT) for 1 h. Insoluble material was removed by centrifugation at 12,000 x g. Cry1Ac, Cry1Ca, and Cry1J (0.5 to 1 mg/ml) were digested for 2 h at room temperature with N
-p-tosyl-L-lysine chloromethyl ketone (TLCK)-treated trypsin (Sigma) at a concentration of 0.2 mg/ml. Cry1Ba was digested with 2% (vol/vol) P. brassicae gut extract (21) for 2 h at room temperature. Insoluble precipitate was removed by centrifugation at 12,000 x g, and the activated toxins were quantified by the method of Bradford (4) using Bio-Rad protein assay solution with BSA as the standard. Quantification and activation were confirmed by resolving the toxins and BSA standards by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Activated toxins were further purified by column chromatography before they were labeled with Na125I.
Column purification of Cry1 toxins.
Activated Cry1Ac was purified by an established protocol (5) that involves anion-exchange fast protein liquid chromatography with an HR5/5 column (Pharmacia) packed with 1 ml of Source 15Q (Pharmacia). This protocol was found to be unsuitable for purification of the other three toxins; in particular, the nonionic buffer required for the column resulted in significant precipitation of Cry1Ca, Cry1J, and Cry1Ba. A new purification protocol was, therefore, developed during this study.
Eighty milligrams of each protoxin was activated in Na2CO3-10 mM DTT-1% (vol/vol) P. brassicae gut extract at pH 10 for 1 h, and this was followed by treatment with DNase I (2 mg) for 30 min. For Cry1Ca a prototype method in which low-pressure adsorption chromatography was used was developed. The toxin was applied to a 10-ml column of hydroxyapatite resin (HA-ultragel; Sigma), which was washed with water to elute nonadsorbing protein. Basic proteins were then eluted with a high-salt buffer (1 mM Na2CO3, 1 mM Na2HPO4, 0.9 M NaCl; pH 8.6). The protein was further eluted with a low-phosphate buffer (10 mM Na2CO3, 10 mM Na2HPO4; pH 8.6), followed by a high-phosphate buffer (500 mM Na2HPO4, 10 mM Na2CO3; pH 8.6), using a one-step gradient. Cry1Ca eluted with the low-phosphate buffer.
To further improve the purification procedure, fast protein liquid chromatography with a Waters 650E system was employed. Prior to adsorption chromatography a size fractionation step with a Superose 12 HR 10/30 column (Pharmacia) was used to remove any small peptides that might have interfered with purification. Toxins were eluted from this column with 1 mM Na2CO3-1 mM Na2HPO4-5 mM DTT (pH 10). Adsorption chromatography was performed with an XK 16/20 column (Pharmacia) packed with 15 ml of 40-µm hydroxyapatite. Activated toxins were loaded directly from the Superose 12 column, and the low-phosphate buffer was applied until all the unbound protein was eluted. Basic proteins were then eluted with a high-salt buffer before a gradient starting with low-phosphate buffer and ending with high-phosphate buffer was established. The toxin eluted several minutes after the gradient had finished.
Iodination of toxins.
Column-purified toxins were iodinated by using the IODO-BEAD (Pierce) method according to the manufacturer's instructions. For each toxin two iodobeads were preincubated in 200 µl of binding buffer (phosphate-buffered saline [PBS]) (8 mM Na2HPO4, 2 mM KH2PO4, 150 mM NaCl; pH 7.4) containing 1 mCi of Na125I (Amersham) for 5 min. Toxins were added at the following concentrations with the following buffers, depending on the method of purification: 25 µg of Cry1J in 800 µl of 10 mM Na2CO3-500 mM Na2HPO4 (pH 8.6) and 120 µg of Cry1Ba in 400 µl of the same buffer; 100 µg of Cry1Ac in 400 µl of 20 mM piperazine-0.6 M NaCl (pH 9.5); and 25 µg of Cry1Ca in 800 µl of 10 mM Na2CO3-10 mM Na2HPO4 (pH 8). Toxins were incubated with the Na125I for 15 min, and free iodine was removed by using PD-10 columns (Pharmacia) equilibrated with PBS. The specific activities of the radiolabeled preparations were as follows: Cry1Ac, 53 Ci/mmol; Cry1Ca, 23 Ci/mmol; Cry1Ba, 20 Ci/mmol; and Cry1J, 157 Ci/mmol.
Saturation binding experiments.
Saturation binding experiments were done to determine the percentage of radiolabeled toxin capable of binding if toxin binding was specific and to identify a suitable concentration of BBMV to use in subsequent homologous competition experiments. 125I-labeled toxins were added to duplicate samples at fixed concentrations (Cry1Ac, 0.9 nM; Cry1Ca, 0.39 nM; Cry1Ba, 1.08 nM; and Cry1J, 0.12 nM) and were equilibrated at room temperature with and without 1,000 nM unlabeled toxin. Various concentrations of BBMV (0 to 0.5 mg/ml) were added to initiate the reaction. Pellets were collected and radioactivity was quantified as described above for the homologous competition experiments. The percentages of radioligands capable of total binding were as follows: Cry1Ac, 10%; Cry1Ca, 1.5%; Cry1Ba, 11%; and Cry1J, 14%.
Homologous competition.
BBMV were incubated with 125I-labeled toxin in 200 µl (final volume) of PBS containing 0.1% (wt/vol) BSA (Sigma). Prior to the addition of BBMV, 125I-labeled toxins were added at fixed concentrations (Cry1Ac, 0.9 nM; Cry1Ca, 0.39 nM; Cry1Ba, 1.08 nM; and Cry1J, 0.12 nM) together with different concentrations of unlabeled toxin as the homologous competitor (0 to 2,000 nM). Most reactions were initiated by adding BBMV to a final concentration of 0.1 mg/ml; the exceptions were the S. exigua reaction mixtures, in which the final concentration was 0.05 mg/ml. The preparations were equilibrated at room temperature for 45 min without shaking, and unbound toxin was separated from bound toxin by centrifugation at 13,500 x g for 10 min. Each pellet containing bound toxin was washed twice with PBS containing 0.1% (wt/vol) BSA. The radioactivity in the pellet was measured with a gamma counter (Cobra II; Packard). Eight concentrations of unlabeled toxin were prepared in duplicate, and the experiments were repeated twice.
Analysis of binding experiments.
Purification protocols designed to remove contaminants from activated toxins have been described previously (14, 30, 31); however, radiolabeling of Cry toxins remains problematic. Typically, small amounts of contaminating peptides are labeled with disproportionate ease, resulting in mixtures in which the labeled ligand accounts for a fraction of the total radioactivity (2, 16, 30, 47). Under these circumstances the specific activity of the tracer is overestimated, which results in underestimation of the total binding site concentration (Bmax). This artifact can be partially corrected by using saturation binding experiments to determine the percentage of radiolabeled mixture that is capable of receptor binding (17) and adjusting the specific activity of the toxin accordingly.
Competition binding data were analyzed using the software package KELL for Windows (version 6; Biosoft, Cambridge, United Kingdom). The data were first processed using RADLIG (34), which estimated the competition constant (Kcom) (nanomolar) and the Bmax (picomoles per milligram). The results of repeated experiments were then coanalyzed by using LIGAND (35) to determine the final binding constants, Kcom, and Bmax. Liang et al. (25) proposed a kinetic analysis for Cry1 binding that considered both reversible and irreversible binding. It was suggested that the Kd value commonly calculated from homologous binding experiments should be designated Kcom to indicate the contribution of both the equilibrium constant for reversible binding (Kd) and the rate of conversion to irreversible binding. We used the term Kcom instead of Kd in recognition of the irreversible binding component that is intrinsic to competition binding assays for Cry toxins.
The LIGAND program also compares single- and multiple-binding-site models, comparing the goodness of fit for the models entered into the program. Whenever possible, binding data were fitted to both one- and two-receptor-site models. These models were then statistically tested by LIGAND for the significantly best fit by using an extra sum of squares F test.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. LC50 values of Cry1 endotoxins administered to neonate and third-instar lepidoptera
|
A comparison of the LC50s of the same protoxin for different insects revealed many insights concerning the target range of the toxin. The following potency data (Table 1) are discussed because we have neonate and third-instar binding data (see Table 3) to compare them to. S. exigua was significantly less susceptible to Cry1J than M. sexta and P. brassicae were (Table 1) at the neonate stage. M. sexta was more susceptible to Cry1Ca than M. brassicae (Table 1) at both the neonate stage (fourfold) and the third-instar stage (ninefold). Cry1Ac was an effective toxin only for M. sexta and P. brassicae. M. sexta neonates were more susceptible to Cry1Ac than P. brassicae neonates (fivefold), but this was not the case for third-instar larvae (Table 1). Cry1Ba was dramatically more potent for P. brassicae than for M. sexta (Table 1) at both larval stages (210-fold for neonates and 490-fold for third-instar larvae). Another noteworthy result is that although Cry1Ba was more potent for P. brassicae than for the other species studied, there were no differences in the LC50s during larval aging (Table 1).
|
View this table: [in a new window] |
TABLE 3. Binding characteristics of 125I-labeled Cry1 toxins as determined by homologous competition assays using BBMV from whole neonate and third-instar larvaea
|
|
View this table: [in a new window] |
TABLE 2. APN activity and enrichment in microscale preparations of BBMV from whole neonate and third-instar larvae
|
For P. brassicae a two-site fit for Cry1Ba was found in neonate BBMV but not in third-instar BBMV (Table 3); however, no changes in the potency of Cry1Ba during development of P. brassicae were observed (Table 1).
For M. brassicae there was a significant increase in Cry1Ca binding site concentration from the neonate stage to the third-instar stage (Table 3); this increase was apparently inversely correlated with resistance to Cry1Ca during larval development (Table 1).
Binding experiments performed with S. exigua and Cry1J revealed no significant difference in either Kcom or Bmax during development (Table 3); this finding agrees well with the bioassay data which revealed no significant differences in LC50s between larval stages (Table 1).
Since A. ipsilon was highly resistant to all four toxins and there were no differences in potency for different developmental stages, BBMV from fifth-instar larvae were used for binding assays. Binding was not observed with Cry1Ba, which correlated with resistance to this toxin. Despite the lack of toxicity, binding was observed with the other three Cry1 toxins; indeed, for Cry1Ca, a two-site fit was determined (Kcom1, 0.21 ± 0.29 nM; Kcom2, 64 ± 27 nM; Bmax1, 0.83 ± 0.9 pmol/mg; Bmax2, 293 ± 107 pmol/mg). For Cry1J the binding values were as follows: Kcom, 121 ± 132 nM; and Bmax, 137 ± 163 pmol/mg. For Cry1Ac Kcom was 310 ± 85.6 nM and Bmax was 2,409 ± 837 pmol/mg.
In addition to neonate and third-instar larvae, binding assays were also performed with fifth-instar M. sexta larvae. LIGAND analysis of fifth-instar data detected two binding sites for Cry1Ac (Kcom1, 0.93 ± 1.6 nM; Kcom2, 74.4 ± 18.4 nM; Bmax1, 5.52 ± 8.9 pmol/mg; Bmax2, 909 ± 146 pmol/mg). However, these binding sites were not found when experiments were performed with M. sexta neonate and third-instar larvae (Table 3). This discrepancy may have resulted from the small quantities of whole larvae used in the third-instar larva binding experiments (see Materials and Methods). However, it may also have been a true reflection of the Cry1Ac binding characteristics of the younger larvae (see below).
Homologous competition binding: comparisons between species treated with the same toxin.
Interestingly, S. exigua neonates were less susceptible to, and had a correspondingly lower binding affinity for, Cry1J than M. sexta and P. brassicae neonates (Tables 1 and 3). M. sexta was more susceptible to Cry1Ca than M. brassicae at both the neonate and third-instar stages, but this was not reflected in the binding data. M. sexta neonates were more susceptible to, and had a correspondingly higher affinity for, Cry1Ac than P. brassicae neonates (Tables 1 and 3). Although Cry1Ba was dramatically more potent for P. brassicae than for M. sexta at both larval stages studied (Table 1), only the binding data for P. brassicae neonates, in which two binding sites were found, correlated with the bioassay results.
|
|
|---|
Aminopeptidase activity was detected in all BBMV studied here, although no clear relationship could be established between APN activity and the potency of Cry1 toxins or the binding of toxins. This finding is supported by the findings of other workers. Lorence et al. (28) showed that the action of Cry1Ac was dependent on its presence but not on its enzymatic activity, and Jenkins et al. (19) showed that APN activity was not directly correlated with toxin binding.
The increased resistance of M. sexta third-instar larvae to Cry1Ac and Cry1Ba may be due to loss of the neonate binding sites (Bmax) for these toxins. There has been one other report correlating the loss of a binding site during larval development with resistance. Rausell et al. (38) showed that one of two Cry1Ab binding sites for Thaumetopoea pityocampa was lost between the first- and second-instar stages, which correlated with 10% mortality for second-instar larvae at the neonate LC50. A complete lack of binding has also been implicated in development of field resistance, most notably in P. xylostella (39).
In this study, P. brassicae was the most susceptible species to Cry1Ba and, correspondingly, the only insect (at the neonate stage) to exhibit a high-affinity binding site for Cry1Ba. Hofmann et al. (14) previously described a correlation between Cry1Ba binding and toxicity for P. brassicae fifth-instar larvae . In this study, these observations were extended to show the significant changes in the binding characteristics of Cry1Ba during larval development in P. brassicae.
Binding data for Cry1Ac and M. sexta show that the binding affinity (Kcom) in neonates may be lower than that in third-instar larvae, which inversely correlates with toxicity. The other inverse correlation between binding and toxicity detected in this study was that observed with Cry1Ca and M. brassicae, which exhibited a significant increase in binding site concentration during larval development despite the resistance seen in the third-instar larvae. Other workers have also had difficulty correlating binding characteristics with toxicity. Luo et al. (31) investigated the relationship between binding and toxicity for S. exigua and Spodoptera frugiperda. High-affinity binding sites were identified for Cry1Bb, Cry1Ca, and Cry1Ac, but the binding constants did not correlate with toxicity. Ballester et al. (2) demonstrated that the loss of a low-affinity binding site for Cry1Ab in P. xylostella resulted in resistance in this organism even though a high-affinity binding site was still available. Liu et al. (27) showed there were no significant differences in Cry1C binding to resistant and susceptible strains of P. xylostella. Van Rie et al. (47) observed that Cry1E had two binding sites in BBMV prepared from M. sexta and Spodoptera littoralis. Although these two insects had similar susceptibilities to Cry1E and similar affinities for the low-affinity binding sites (correlating with toxicity), the high-affinity binding site for M. sexta had a Kcom at least 10 times lower than the Kcom for S. littoralis and was therefore not positively correlated with potency.
The conflicting results mentioned above could be due in part to interpretation of the binding data. For example, most bioassays have been done with neonate larvae, whereas binding assays are usually done with midguts dissected from fifth-instar larvae (12, 31, 50). However, as we have clearly shown in this study, there are many instances in which toxicity decreases dramatically during larval development. Therefore, using binding data for a larval stage different from the stage used for a bioassay could be problematic and in some cases could lead to misinterpretation of data (e.g., the data for M. sexta fifth-instar larvae in this study). In studies in which the workers have compared toxicity and binding data for corresponding larval stages, positive correlations have often, although not always, been found (25, 37, 38; this study).
Interpretation of binding data is further complicated by the irreversible associations, as well as the reversible associations, of the toxins with BBMV; perhaps the more subtle differences in potency may go undetected unless these two components are measured separately. Liang et al. (25) showed the importance of obtaining such measurements by demonstrating that irreversible binding was directly correlated with toxicity but not with Bmax and Kd. Wu and Dean (51) found that there was a direct correlation between potency and irreversible binding of the loop III block mutant but no correlation with reversible binding. Thus, even distinguishing between irreversible binding and reversible binding can make data difficult to interpret, as concluded by Luo et al. (31), who found that Cry1Ac, Cry1Ca, and Cry1Bb bound irreversibly to S. exigua BBMV, even though the toxicities of the molecules were different. In this study, the homologous competition assay was a useful screening technique; it highlighted where binding was or was not clearly related to potency, and indeed, Liang et al. (25) supported the use of this type of assay for comparative purposes.
Cry1 toxin binding is necessary, although not sufficient, for toxicity (12, 37, 50). Although positive correlations between toxicity and binding have been found in this and other studies, Lee et al. (23, 24) have pointed out that nonfunctional receptors may be present on the surface of BBMV, which would further complicate interpretation of binding data. The presence of nonfunctional receptors may go some way in explaining the binding observed in A. ipsilon with Cry1Ac, Cry1Ca, and Cry1J and in M. sexta with Cry1Ba despite the resistance of these insects to these toxins.
In this study we investigated the possibility that changes in binding properties may influence changes in toxin potency during larval development using five lepidopteran species and four Cry1 toxins. Binding characteristics did not positively correlate with potency in every case in this study. The difficulties in correlating APN activity and binding parameters with potency underscore the complexity of the mode of action of these toxins, and further study of the toxins is warranted.
We thank T. Sawyer for technical assistance.
|
|
|---|
-endotoxin action on insect-midgut-membrane permeability using a light-scattering assay. Eur. J. Biochem. 214:771-778.[Medline]
-endotoxin combinations. Biochem. J. 270:133-136.[Medline]
-endotoxin by protein blot analysis. Appl. Environ. Microbiol. 57:2816-2820.
-endotoxins is correlated with the presence of high-affinity binding sites in the brush border membrane of target insect midguts. Proc. Natl. Acad. Sci. USA 85:7844-7848.
-endotoxin of Bacillus thuringiensis. Comp. Biochem. Physiol. 120:197-204.[CrossRef]
-endotoxin in the brush border membrane of the lepidopteran Manduca sexta is aminopeptidase N. Mol. Microbiol. 11:429-436.[Medline]
-endotoxins to gypsy moth brush border membrane vesicles is directly correlated to toxicity. J. Biol. Chem. 270:24719-24724.
-endotoxin iodination and binding by sodium dodecyl sulfate treatment and renaturation. Appl. Environ. Microbiol. 60:2905-2910.
-endotoxins using brush border membrane vesicles of Spodoptera exigua and Spodoptera frugiperda. Appl. Environ. Microbiol. 65:457-464.
-endotoxin in the brush border membrane of Manduca sexta. Insect Biochem. Mol. Biol. 26:783-791.[CrossRef]
-endotoxin binding and pore formation. Insect Biochem. Mol. Biol. 27:735-743.[CrossRef][Medline]
-endotoxin: mutations at domain II of Cry1Ab enhance receptor affinity and toxicity toward gypsy moth larvae. Proc. Natl. Acad. Sci. USA 93:14338-14343.
-endotoxin: effects on insect and mammalian cells in vitro and in vivo. J. Cell Sci. 60:181-197.[Abstract]
-endotoxins. Importance of specific receptors on the brush border membrane of the mid-gut of target insects. Eur. J. Biochem. 186:239-247.[Medline]
-endotoxin gene of Bacillus thuringiensis var. israelensis to a specific plasmid by curing analysis. FEBS Lett. 158:45-49.[CrossRef]
-endotoxins to gypsy moth larvae is inversely related to the affinity of binding sites on midgut brush border membranes for the toxins. Experientia 46:475-477.[CrossRef][Medline]
-endotoxin. J. Mol. Biol. 255:628-640.[CrossRef][Medline]
-endotoxin toxic to three insect orders. Ph.D. thesis. University of Cambridge, Cambridge, United Kingdom.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»